Alicyn Campbell

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Suresh S. Ramalingam, Fiona Blackhall, Maciej Krzakowski et al. · Journal of Clinical Oncology · 2012 · 266 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

Karen L. Reckamp, Giuseppe Giaccone, D. Ross Camidge et al. · Cancer · 2014 · 144 citations · Full text

Medicine, Oncology, Pharmacology +17

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials

Andrew Bottomley, Madeline Pe, Jeff A. Sloan et al. · Clinical Trials · 2018 · 49 citations · Full text

Pharmacy, Oncology, Clinical Data Management +16

Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events: Methods for item selection in industry-sponsored oncology clinical trials

Peter C. Trask, Amylou C. Dueck, Elisabeth Piault et al. · Clinical Trials · 2018 · 40 citations

Medicine, Oncology, Clinical Pharmacology +11

PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E).

Alicyn Campbell, Karen L. Reckamp, D. Ross Camidge et al. · Journal of Clinical Oncology · 2010 · 39 citations

Medicine, Oncology, Pharmacology +15